Tech Company Financing Transactions
Radiomer Therapeutics Funding Round
Fannin participated in a Seed funding round for Radiomer Therapeutics. The round closed on 5/30/2024.
Transaction Overview
Company Name
Announced On
5/30/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to continue development of its radiopharmaceutical/ radioligand therapy platform and programs.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
3900 Essex Lane 575
Houston, TX 77027
USA
Houston, TX 77027
USA
Phone
Website
Email Address
Overview
Radiomer Therapeutics, Inc. is developing Radiomers, targeted radiopharmaceuticals / radioligand therapies, for theranostic applications using its novel Raptamer platform. Raptamers are a novel targeting vector that consist of a single-stranded (ss)DNA backbone decorated with peptide-like side chains to add chemical diversity and improve binding affinity. The modular Raptamer structure allows the addition of a variety of chelators and isotope payloads.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Atul Varadhachary
Chief Financial Officer
Mark Worscheh
Chief Medical Officer
Philip Breitfeld
VP - Operations
Michael Heffernan
Browse more venture capital transactions:
Prev: 5/30/2024: NexGami venture capital transaction
Next: 5/30/2024: Doconomy venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs